University of Cambridge > > Cambridge Society for the Application of Research (CSAR) > Enhancing the Brain and Wellbeing in Health and Disease

Enhancing the Brain and Wellbeing in Health and Disease

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact John Cook.

How more effective treatments are being developed through an understanding of the neural basis of cognitive, emotional and behavioural dysfunction

While people frequently monitor their physical health, using wearable tech and other devices, we are much less likely to consider our brain health. The most important role of countries is to promote their citizens’ cognitive resources in order to prosper both economically and socially. With an ever more competitive global environment and the rise of artificial intelligence (AI), it is important to think how we can boost brain power and wellbeing. In addition, the importance of early detection of mental health problems in order to treat them effectively is essential to prevent these disorders from becoming chronic and debilitating. In this lecture Prof. Sahakian will focus on how to improve brain health, motivation and wellbeing including the use of cognitive enhancing or ‘smart drugs’ and also the use of brain training apps.

Prof. Sahakian’s research is aimed at understanding the neural basis of cognitive, emotional and behavioural dysfunction in order to develop more effective pharmacological and psychological treatments. The focus of her lab is on early detection, differential diagnosis and proof of concept studies using cognitive enhancing drugs. This research utilises neuropsychological tests, such as the CANTAB tests, which she co-invented and a focus remains on the development of novel tests. Current study participants include healthy volunteers and patient groups with brain injury, Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD), obsessive compulsive disorder, substance abuse, depression and mania. Techniques used include psychopharmacological, neuropsychological, neuroimaging (fMRI and PET ) and genetic ones. Results from recent studies of ecstasy use and cognitive enhancement using methylphenidate, modafinil and atomoxetine have led to an interest in pharmacogenomics and neuroethics.

Add to calendar

Find out more about this event

Find out more about CSAR membership

Download the winter programme

This talk is part of the Cambridge Society for the Application of Research (CSAR) series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2024, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity